Literature DB >> 2032801

Microspheres of biodegradable polymers as a drug-delivery system in the vitreous.

T Moritera1, Y Ogura, Y Honda, R Wada, S H Hyon, Y Ikada.   

Abstract

Microspheres of biodegradable polymers were evaluated as a potential controlled-release drug-delivery system in the vitreous. The microspheres were prepared with polymers of poly(lactic acid) or copolymers of glycolic acid and lactic acid. The release of 5-fluorouracil (5-FU) from the microspheres was studied in vitro. Poly(lactic acid) microspheres released 70-85% of total 5-FU over 7 days. Microspheres of polymers with a smaller molecular weight released the drug more rapidly. Copolymer microspheres released 98% of 5-FU over 2 days. The rate of drug release was controllable by changing the molecular weight of the polymers or using a matrix of copolymer. The intravitreal kinetics of the microspheres were studied in ten rabbits in vivo. A suspension of microspheres was injected into the vitreous cavity of five normal eyes and five vitrectomized eyes. By 48 +/- 5.2 days after injection, the microspheres disappeared from the vitreous cavity in the five normal eyes. Clearance from the vitreous cavity was accelerated in the five rabbits that underwent vitrectomy (14 +/- 2.4 days; P less than 0.001). No difference was found in the b waves of electroretinograms before and after injection of the microspheres. The histologic study showed no abnormal findings as a result of the injection. These results suggested that microspheres of biodegradable polymers may be a potential delivery system for the controlled release of drugs in the vitreous.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032801

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  21 in total

Review 1.  Biodegradable implants for sustained drug release in the eye.

Authors:  Susan S Lee; Patrick Hughes; Aron D Ross; Michael R Robinson
Journal:  Pharm Res       Date:  2010-06-10       Impact factor: 4.200

2.  Studies on a novel doughnut-shaped minitablet for intraocular drug delivery.

Authors:  Yahya E Choonara; Viness Pillay; Trevor Carmichael; Michael P Danckwerts
Journal:  AAPS PharmSciTech       Date:  2007-12-28       Impact factor: 3.246

Review 3.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

Review 4.  Advances in ocular drug delivery systems.

Authors:  Jennifer J Kang-Mieler; Kayla M Rudeen; Wenqiang Liu; William F Mieler
Journal:  Eye (Lond)       Date:  2020-02-18       Impact factor: 3.775

Review 5.  Nanocarriers of nanotechnology in retinal diseases.

Authors:  Ali M Al-Halafi
Journal:  Saudi J Ophthalmol       Date:  2014-03-05

6.  Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.

Authors:  Haihua Zheng; Zhimin Wang; Peijuan Wang; Yaqin Liu; Zhaoxin Jiang; Qianying Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-27       Impact factor: 3.117

7.  Passage of drugs through different intraocular microdialysis membranes.

Authors:  J Waga; B Ehinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

Review 8.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

9.  Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases.

Authors:  Namdev B Shelke; Rajendra Kadam; Puneet Tyagi; Vidhya R Rao; Uday B Kompella
Journal:  Drug Deliv Transl Res       Date:  2011-02       Impact factor: 4.617

10.  Studies on Indomethacin Intraocular Implants Using Different in vitro Release Methods.

Authors:  J Balasubramaniam; A Srinatha; J K Pandit
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.